[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mahidol University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":712},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,77,0,25,[9,55,85,109,138,170,191,220,256,287,316,333,360,387,420,451,473,504,528,554,579,601,630,657,684],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100652850","national-survey-of-chronic-occupational-pain-in-thai-anesthesia-providers-100652850",false,"NCT07778381","National Survey of Chronic Occupational Pain in Thai Anesthesia Providers","Prevalence, Impacts, and Associated Factors of Chronic Occupational Pain Among Anesthesiologists and Nurses Anesthetists in Thailand: A National Survey","Inclusion Criteria:\n\n* Currently practicing as an anesthesiologist, anesthesia resident, or nurse anesthetist in a hospital in Thailand.\n* Aged between 25 and 60 years.\n* Have been working in their current clinical position and performing anesthesia-related tasks for at least 6 months.\n\nExclusion Criteria:\n\n* Currently on extended leave (e.g., long-term sick leave, maternity leave, or study leave) during the survey period.\n* Unwilling or unable to provide informed consent to participate in the study.",true,"ALL","25 Years","60 Years",{"count":22,"type":23},1800,"ESTIMATED","1 Day","OBSERVATIONAL","The purpose of this nationwide cross-sectional survey is to determine the prevalence, multidimensional impacts, and associated factors of chronic occupational pain among anesthesiologists and nurse anesthetists in Thailand. Due to the physically demanding nature of anesthesia practice-such as prolonged standing, awkward postures during airway management, and high-stress environments-work-related musculoskeletal disorders are highly prevalent but often underreported. This study aims to collect self-reported data via an anonymous online questionnaire to assess pain severity, specific anatomical locations, economic burdens (including absenteeism and presenteeism), and the overall impact on the health-related quality of life. Ultimately, the findings from this study will help establish a national evidence-based database to improve workplace safety, inform occupational health policies, and enhance the overall well-being of anesthesia providers in Thailand.",[28,29,30,31],"Chronic Pain","Musculoskeletal Pain","Occupational Pain","Occupational Diseases",[33,34,35,36,37,38,39,40,41,42],"Anesthesiologists","Nurse Anesthetists","Anesthesia Providers","Healthcare Personnel","Work-Related Musculoskeletal Disorders (WMSDs)","Occupational Health","Ergonomics","Quality of Life","Presenteeism","Absenteeism","NOT_YET_RECRUITING","2026-08-19",{"date":46,"type":47},"2026-08-21","ACTUAL",{"date":49,"type":23},"2026-08-15",{"date":51,"type":23},"2027-01-01",{"name":53,"class":54},"Mahidol University","OTHER",{"id":56,"slug":57,"hasResults":12,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100611399","phase-4-beta-lactam-plus-levofloxacin-to-enhance-therapy-in-streptococcal-septicemia-100611399","NCT07240077","Beta-lactam Plus Levofloxacin to Enhance Therapy in Streptococcal Septicemia","Beta-lactam Monotherapy Versus Beta-lactam Plus Levofloxacin for the Treatment of Streptococcal Bacteremia: A Multicenter, Randomized, Double-Blind, Pragmatic Trial","BLESS","Inclusion Criteria:\n\n1. Adults age\\>18 years\n2. Blood culture positive for Streptococcus (\\\u003C72 hours before enrollment)\n\n   * at least 1 bottle of S. pyogenes, S. agalactiae, S. pneumoniae, S. suis\n   * at least 2 bottle of other Streptococci\n3. Receiving or having plan of receiving beta-lactam therapy\n\nExclusion Criteria:\n\n1. Known allergy to beta-lactam or fluroquinolone antibiotics\n2. Pregnancy or lactating mother\n3. EKG with QT prolongation\n4. Diagnosis of infective endocarditis","18 Years",{"count":65,"type":23},165,"INTERVENTIONAL",[68],"PHASE4","A double-blind randomized controlled trial comparing beta-lactam plus levofloxacin versus beta-lactam monotherapy for the treatment of Streptococcal bacteremia",[71,72],"Bacteremia","Streptococcus Infection",[74,75,76],"bacteremia","streptococcus","levofloxacin","RECRUITING",{"date":46,"type":47},{"date":80,"type":47},"2026-01-08",{"date":82,"type":23},"2028-12-31",{"name":53,"class":54},4,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":66,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100652645","benefit-of-moderate-intensity-exercise-in-patients-with-clinical-quiescent-inflammatory-bowel-disease-100652645","NCT07775794","Benefit of Moderate Intensity Exercise in Patients With Clinical Quiescent Inflammatory Bowel Disease","IBDEXERCISE","Inclusion Criteria:\n\n* Patients diagnosed with Crohn's disease or Ulcerative colitis.\n* Aged between 18 and 65 years.\n* Disease must be in clinical remission for at least 2 months prior to study enrollment, as defined by: Crohn's disease: Harvey-Bradshaw Index \\\u003C 5 Ulcerative colitis: Mayo Ulcerative Colitis Subscore \\\u003C 2\n* Not currently receiving corticosteroids,\n* If receiving immunomodulators or biologic therapy, the treatment regimen must be stable for at least 2 months prior to enrollment.\n* Participants must have access to and be capable of using online communication tools and digital platforms.\n\nExclusion Criteria:\n\n* Patients with medical conditions that limit the ability to exercise, including Severe joint pain or inflammatory arthritis affecting ambulation or mobility Advanced cardiac disease (New York Heart Association Class ≥ 2) Chronic lung disease or pulmonary hypertension Liver cirrhosis Chronic kidney disease stage 3 or higher\n\nPoorly controlled non-communicable diseases, such as:\n\nHypertension (BP ≥ 160\u002F100 mmHg) Diabetes mellitus with poor glycemic control (HbA1c ≥ 9% or requiring insulin therapy)\n\n* Patients who already engage in moderate-intensity exercise for more than 60 minutes per week on a regular basis.\n* Pregnant individuals or those planning to become pregnant during the study period.\n* Patients planning to undergo treatment changes or surgery within the next 3 months, or who have had surgery within the past 6 months.","65 Years",{"count":94,"type":23},50,[96],"NA","The goal of this Randomised controlled trial is to investigate the effect of exercise on changes in quality of life in in patients with clinical quiescent Inflammatory bowel Disease. The main question it aims to answer\n\n* The Relationship Between Moderate-Intensity Exercise and Quality of Life in Patients with clinical quiescent nflammatory Bowel Disease Over a Six-Month Period\n* To examine the association between the recurrence of clinical symptoms(defined as a Harvey-Bradshaw Index \\> 5 for Crohn's disease and a Mayo Ulcerative Colitis Subscore \\> 2 for Ulcerative Colitis) and changes in inflammatory markers in blood and stool, comparing patients with clinical quiescent inflammatory bowel disease (IBD) who engage in regular exercise versus those who do not.\n* To evaluate the relationship between higher levels of physical activity and quality of life, sleep quality, and stress levels in patients with clinical quiescent IBD.\n* To assess changes in body composition including body mass index (BMI), fat mass, total muscle mass, skeletal muscle mass, and skeletal muscle index between patients who exercise regularly and those who do not.\n\nIntervened participants will be encoraged in moderate-intensity exercise for at least 30 minutes per session, three times per week or more, under the supervision and guidance of a sports scientist compared participants who do not receive exercise training or supervision from a sports scientist.",[99],"Inflammatory Bowel Disease (IBD)","2026-08-18",{"date":102,"type":47},"2026-08-20",{"date":104,"type":47},"2024-11-17",{"date":106,"type":23},"2026-12-31",{"name":53,"class":54},1,{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":66,"phases":118,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":108},"100652680","intestinal-ultrasound-guided-management-in-inflammatory-bowel-disease-100652680","NCT07775352","Intestinal Ultrasound Guided Management in Inflammatory Bowel Disease","A Randomized Controlled Trial Comparing Standard of Care With and Without Intestinal Ultrasound Guidance in Patients With Inflammatory Bowel Diseases","Inclusion Criteria:\n\n* Diagnosis of inflammatory bowel disease for more than 2 months\n* Age 18 years or older\n* Undergoing endoscopy at enrollment for assessment of disease severity\n\nExclusion Criteria:\n\n* Pregnancy\n* Unstable underlying medical conditions\n* Inflammatory bowel disease limited to the distal rectum (within 10 cm of the anal verge) or perianal disease only\n* Biologic failure",{"count":117,"type":23},137,[96],"This randomized controlled trial evaluates whether adding point-of-care intestinal ultrasound (IUS) to standard of care changes clinical management in patients with inflammatory bowel disease (IBD). Adult patients with Crohn's disease or ulcerative colitis undergoing colonoscopy for disease assessment are randomized 1:1 to standard of care plus IUS at every visit, or standard of care alone, and followed for 48 weeks. The primary outcome is the proportion of patients with a change in treatment.",[121,122,123],"Inflammatory Bowel Diseases","Crohn Disease","Colitis, Ulcerative",[125,126,127,128,129,130],"intestinal ultrasound","IBD","point-of-care ultrasound","treat-to-target","bowel wall thickness","IBUS-SAS","2026-08-16",{"date":102,"type":47},{"date":134,"type":47},"2026-03-25",{"date":136,"type":23},"2028-03",{"name":53,"class":54},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":18,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":66,"phases":150,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":108},"100594384","phase-1-mesenchymal-stem-cells-with-cooling-therapy-for-infants-with-hypoxic-ischemic-encephalopathy-100594384","NCT07018739","Mesenchymal Stem Cells With Cooling Therapy for Infants With Hypoxic-Ischemic Encephalopathy","Efficacy of Using Mesenchymal Stem Cells With Therapeutic Hypothermia in Infants With Perinatal Hypoxic-Ischemic Encephalopathy: A Double Blind, Randomized Controlled Trial","SiSTEM-NEO","Inclusion Criteria:\n\n* Term and late-preterm infants (gestational age ≥34 weeks)\n* Diagnosed with moderate to severe HIE based on modified Sarnat staging\n* Received TH per standard protocol\n* Parental consent obtained\n\nExclusion Criteria:\n\n* Major congenital anomalies or genetic syndromes\n* Severe sepsis or active infection\n* Severe coagulopathy or bleeding disorders\n* Multi-organ failure","4 Days","9 Days",{"count":149,"type":23},40,[151,152],"PHASE1","PHASE2","Hypoxic-ischemic encephalopathy (HIE) is a serious condition in newborns caused by lack of oxygen and blood flow around the time of birth. Standard treatment with cooling therapy (therapeutic hypothermia) lowers the risk of death or disability, but many infants still suffer long-term problems.\n\nThis study will test whether adding stem cell therapy after cooling can further improve outcomes. The stem cells are taken from donated human placentas (Wharton's jelly-derived mesenchymal stem cells, MSCs). The cells are prepared under strict laboratory standards and checked for safety.\n\nInfants with moderate to severe HIE who have completed cooling will be randomly assigned to receive either three intravenous infusions of MSCs or placebo within the first 10 days of life. Each infusion is given over about 30 minutes while the infant is closely monitored.\n\nResearchers will follow participants for up to 2 years. The main outcome is whether MSC treatment can reduce the combined risk of death or serious developmental delay at 1 year of age. The study will also track brain MRI findings, safety events, and developmental progress at 2 years.",[155,156],"Hypoxic-Ischemic Encephalopathy, Neonatal","Brain Injuries, Hypoxic-Ischemic",[158,159,160,161],"Perinatal HIE","Mesenchymal stem cells","Wharton's jelly","therapeutic hypothermia","2026-08-10",{"date":164,"type":47},"2026-08-12",{"date":166,"type":23},"2026-09",{"date":168,"type":23},"2033-12",{"name":53,"class":54},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":66,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":108},"100651098","comparison-of-efficacy-and-safety-of-speedboat-device-and-needle-knife-for-colorectal-endoscopic-submucosal-dissection-a-multicenter-randomized-study-100651098","NCT07754955","Comparison of Efficacy and Safety of Speedboat Device and Needle Knife for Colorectal Endoscopic Submucosal Dissection: a Multicenter Randomized Study","Inclusion Criteria:\n\n* Age 18 or above with large non-pedunculated colorectal polyp size \\> 20 mm. in which 1st endoscopist decided that lesion cannot be resected with endoscopic mucosal resection to achieve en bloc resection\n\nExclusion Criteria:\n\n1. Patients who have coagulopathy which is contraindicated for colonoscopy and polypectomy (Prothrombin time \\> 3-second ULN, INR \\> 1.5, Platelet \\\u003C 50,000)\n2. The non-pedunculated lesion that was recurrence from the previous polypectomy or ESD\n3. Suspected deep submucosal invasion using image-enhanced endoscopy by expert endoscopist\n4. Patients who were diagnosed with inflammatory bowel disease\n5. Pregnancy or breastfeeding\n6. A patient who is unable to provide consent",{"count":177,"type":23},80,[96],"The goal of this clinical trial is to learn whether a new endoscopic device called the Speedboat works as well or better than the standard needle knife for removing large colonic nonpedunculated polyps. The study will also evaluate the safety of the Speedboat device.\n\nThe main aims of the study are:\n\n* To compare the resection speed of colorectal endoscopic submucosal dissection (ESD) using the Speedboat device versus the standard needle knife.\n* To compare the en bloc resection rate and curative (R0) resection rate between the two techniques.\n* To evaluate the safety of using the Speedboat device compared with the needle knife in colorectal ESD.\n\nWhat will happen in this study Adults aged 18 years or older who have a large, flat colorectal polyp (greater than 20 mm) that cannot be safely removed with standard snare polypectomy may take part.\n\nParticipants will be randomly assigned (like flipping a coin) to one of two groups:\n\n* Speedboat group: The lesion will be removed using the Speedboat device, which combines injection, cutting, and bleeding control in one tool.\n* Needle knife group: The lesion will be removed using the standard needle knife and other separate tools for injection and hemostasis.\n\nWhat participants will do Stay one night in the hospital before the colonoscopy for bowel preparation. Undergo colonoscopy and lesion removal under anesthesia. Have blood tests and monitoring for one day after the procedure. Be followed for two weeks to check for any complications. Have a follow-up colonoscopy 6-12 months later, depending on pathology results.\n\nWhere and how the study will be done\n\nThe study will take place at five hospitals in Thailand:\n\nFaculty of Medicine Siriraj Hospital, Mahidol University King Chulalongkorn Memorial Hospital Rajavithi Hospital National Cancer Institute of Thailand Phra Nakhon Si Ayutthaya Hospital\n\nAbout 80 participants will join the study. All procedures will be performed by experienced endoscopists who have performed at least 50 colorectal ESD cases.",[181],"Non-pedunculated Colorectal Polyp Size > 20 mm",[183],"Endoscopic submucosal dissection, needle knfe, Speedboat","2026-08-05",{"date":162,"type":47},{"date":187,"type":47},"2024-10-04",{"date":189,"type":23},"2027-09-30",{"name":53,"class":54},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":66,"phases":201,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":108},"100649690","phase-4-efficacy-of-melatonin-treatment-on-sleep-quality-improvement-in-inflammatory-bowel-disease-patients-with-clinical-remission-100649690","NCT07737665","Efficacy of Melatonin Treatment on Sleep Quality Improvement in Inflammatory Bowel Disease Patients With Clinical Remission","Efficacy of Melatonin Treatment on Sleep Quality Improvement in Inflammatory Bowel Disease Patients With Clinical Remission: A Randomized Double-Blind Placebo-Controlled Trial","Melatonin IBD","Inclusion Criteria:\n\n* IBD patients with clinical remission Crohn's disease: HBI \\\u003C 5 Ulcerative colitis: Partial Mayo score 0-1 w\u002Fo bloody stool\n* Age \\> 18 years\n* PSQI score \\> 5\n* No medical adjustment for 2 months and use corticosteroids not more than Prednisolone equivalent 5 mg\u002Fday\n\nExclusion Criteria:\n\n* Current alcohol or substance abuse\n* High risk for OSA (STOP-BANG score \\> 5)\n* Psychiatric problem: PHQ-9 score \\> 20 or GAD-7 score \\> 20\n* Hypnotic drug use and unable to hold for 1week before trial\n* Shift worker",{"count":200,"type":23},90,[68],"Sleep disturbances are common in patients with inflammatory bowel disease (IBD) and are associated with increased disease activity and reduced quality of life. Melatonin, a hormone regulating circadian rhythms, has shown potential anti-inflammatory and sleep-promoting effects in preliminary studies. This study aimed to evaluate the efficacy of melatonin supplementation on sleep quality in IBD patients in clinical remission.",[204],"IBD (Inflammatory Bowel Disease)",[206,207,208,209,210,211],"inflammatory bowel disease","melatonin","sleep quality","Pittsburgh Sleep Quality Index","quality of life","fecal calprotectin","2026-08-01",{"date":214,"type":47},"2026-08-04",{"date":216,"type":47},"2025-04-01",{"date":218,"type":23},"2027-04-30",{"name":53,"class":54},{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":66,"phases":230,"briefSummary":231,"conditions":232,"keywords":238,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":108},"100647585","effects-of-policosanol-and-exercise-on-fitness-and-lipids-in-people-with-elevated-blood-lipids-100647585","NCT07710261","Effects of Policosanol and Exercise on Fitness and Lipids in People With Elevated Blood Lipids","Effect of Policosanol Supplementation Combined With Concurrent Exercise Training on Physical Fitness and Lipid Profiles in Healthy Volunteers With Elevated Blood Lipid But Not Required Medical Treatment","Inclusion Criteria:\n\n* Men and women aged 25 to 59 years.\n* BMI between 18.5 and 29.9 kg\u002Fm².\n* Diagnosed with or presenting with dyslipidemia within the past 3 months, based on laboratory assessment at baseline or a standard laboratory report issued within the past 3 months, according to the National Cholesterol Education Program Adult Treatment Panel III criteria, defined by at least one of the following:\n* Total cholesterol ≥ 200 mg\u002FdL;\n* Low-density lipoprotein cholesterol ≥ 130 mg\u002FdL and \\\u003C 190 mg\u002FdL;\n* High-density lipoprotein cholesterol \\\u003C 40 mg\u002FdL in men;\n* High-density lipoprotein cholesterol \\\u003C 50 mg\u002FdL in women;\n* Triglycerides ≥ 150 mg\u002FdL.\n* Free from chronic or comorbid conditions that contraindicate participation in aerobic or resistance exercise.\n* Cleared for physical activity based on the Physical Activity Readiness Questionnaire for Everyone.\n* Not regularly physically active during the preceding 3 months, defined as fewer than 3 exercise sessions per week or less than 150 minutes of exercise per week.\n* Able and willing to participate in the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Current or recent use within the past 3 months of lipid-lowering medications or dietary supplements known to influence lipid metabolism, including statins, fibrates, niacin, omega-3 fatty acids, red yeast rice, or policosanol.\n* Known allergy or hypersensitivity to policosanol, sugarcane derivatives, capsule components, or any excipients in the supplement formulation.\n* Presence of chronic or comorbid conditions that may make exercise participation unsafe, including but not limited to cardiovascular disease, chronic obstructive pulmonary disease, severe arthritis, osteoporosis, uncontrolled diabetes, gastrointestinal disorders, or neurological impairments affecting movement control.\n* High-risk lifestyle factors, including heavy smoking, excessive alcohol consumption, or use of recreational drugs.\n\nInability to comply with the study protocol, including inability to participate in the exercise program when assigned or inability to attend scheduled follow-up assessments.\n\n\\- Refusal or inability to provide written informed consent independently.","59 Years",{"count":229,"type":23},120,[96],"This study will evaluate the effects of policosanol supplementation, concurrent exercise training, and their combination on physical fitness, muscle recovery, inflammatory markers, and blood lipid profiles in adults with elevated blood lipids who are not currently indicated for lipid-lowering medication.\n\nParticipants will be randomly assigned to one of four groups for 12 weeks: policosanol plus exercise training, policosanol alone, placebo plus exercise training, or placebo without structured exercise training. Participants assigned to the supplementation groups will take policosanol 5 mg per day, while those assigned to the placebo groups will take a matching placebo. Participants assigned to the exercise groups will complete a standardized concurrent exercise training program combining aerobic and resistance exercise.\n\nThe study will compare changes in physical fitness, lipid profiles, and selected blood biomarkers before and after the intervention. The findings may help determine whether low-dose policosanol, alone or combined with exercise training, can support cardiometabolic health and physical fitness in adults with dyslipidemia.",[233,234,235,236,237],"Dyslipidemia","Elevated Blood Lipids","Physical Fitness","Exercise Training","Muscle Function, Handgrip Strength Test",[239,240,241,242,243,244,245,246,235,233,247],"Policosanol","Octacosanol","Dietary Supplement","Concurrent Exercise Training","Aerobic Exercise","Resistance Exercise","Blood Lipid Profile","Muscle Function","Nutraceutical","2026-07-15",{"date":250,"type":47},"2026-07-17",{"date":252,"type":23},"2026-06-22",{"date":254,"type":23},"2027-01-29",{"name":53,"class":54},{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":264,"minAge":63,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":66,"phases":267,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":108},"100647392","phase-3-hypofractionated-chemoradiotherapy-for-cervical-cancer-100647392","NCT07709650","Hypofractionated Chemoradiotherapy for Cervical Cancer","HYPOfractionated Whole Pelvic Concurrent Chemoradiotherapy in Cervical Cancer (HYPOCx Trial): A Phase III Randomized Controlled Trial","HYPOCx","Inclusion Criteria:\n\n1. Cancer of the uterine cervix considered suitable for curative treatment with definitive radio-(chemo)therapy including imaged-guided BT\n2. Positive biopsy showing squamous-cell carcinoma, adenocarcinoma, or adeno-squamous cell carcinoma of the uterine cervix\n3. Locally advanced staging according to FIGO 2018 and TNM guidelines (Stage IA1-IVA)\n4. MRI of the pelvis at diagnosis is performed\n5. MRI, CT, or PET-CT of the retroperitoneal space and abdomen at diagnosis is performed\n6. MRI with the applicator in place at the time of (first) BT will be performed\n7. GFR ≥ 50 mL\u002Fmin\n8. Patient informed consent\n\nExclusion Criteria:\n\n1. Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin\n2. Small cell neuroendocrine cancer, melanoma and other rare cancers in the cervix\n3. Metastatic disease beyond intervertebral disc L2\u002F3 level\n4. Previous pelvic or abdominal radiotherapy\n5. Previous total or subtotal hysterectomy\n6. Combination of preoperative radiotherapy with surgery\n7. Patients receiving BT only\n8. Patients receiving EBRT only\n9. Patients receiving neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg\u002Fm2).\n10. Contra-indications to MRI\n11. Contra-indications to BT","FEMALE",{"count":266,"type":23},250,[268],"PHASE3","Cervical cancer remains a major health problem in Thailand and other lowand middle-income countries. The current standard treatment for locally advanced cervical cancer consists of conventionally fractionated external beam radiotherapy delivered over 5-7 weeks with concurrent chemotherapy, followed by brachytherapy. This prolonged treatment schedule requires frequent hospital visits and may limit access to care. Hypofractionated radiotherapy delivers a higher dose of radiation per treatment session while maintaining a comparable total radiation dose, thereby reducing the overall treatment duration. Preliminary studies suggest that hypofractionated chemoradiotherapy using modern radiotherapy techniques may provide similar disease control and acceptable toxicity compared with conventional treatment, while improving treatment convenience and reducing healthcare burden. This multicenter phase III randomized controlled trial aims to compare hypofractionated whole pelvic concurrent chemoradiotherapy with conventional chemoradiotherapy in patients with early-stage node-positive and locally advanced cervical cancer. The study will evaluate nodal control and overall survival, as well as tumor response, treatment-related toxicities, quality of life, and cost-effectiveness.",[271],"Cervival Cancer",[273,274,275,276,277,278],"Cervical Cancer","Hypofractionated Radiotherapy","Conventional Radiotherapy","Whole Pelvic Radiotherapy","Chemoradiotherapy","Brachytherapy","2026-07-12",{"date":281,"type":47},"2026-07-16",{"date":283,"type":23},"2026-08",{"date":285,"type":23},"2033-06",{"name":53,"class":54},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":66,"phases":296,"briefSummary":297,"conditions":298,"keywords":303,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":108},"100645792","phase-2-steroid-sparing-regimen-with-olanzapine-and-palonosetron-for-emetic-prevention-for-high-dose-cisplatin-100645792","NCT07699276","Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin","Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study","Inclusion Criteria:\n\n* histologically confirmed solid malignancy\n* scheduled for first cycle of cisplatin at dosage of at least 50 mg\u002Fm2\n\nExclusion Criteria:\n\n* pregnancy\n* pelvic or abdominal radiation within 4 weeks\n* uncontrolled brain metastasis\n* other moderate or high emetic risk chemotherapy on day 2-5\n* untreated gut obstruction\n* known allergy or severe adverse effect from palonosetron or olanzapine\n* AST\u002F ALT \\> 2.5x or serum creatinine clearance less than 50 ml\u002Fmin",{"count":295,"type":23},95,[152],"A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting",[299,300,301,302],"Cancer (Solid Tumors)","Vomiting","Cisplatin","Olanzapine",[304,305,306,307],"cisplatin","chemotherapy induced nausea vomiting","dexamethasone sparing","olanzapine","2026-07-07",{"date":310,"type":47},"2026-07-13",{"date":312,"type":47},"2026-02-10",{"date":314,"type":23},"2027-11-15",{"name":53,"class":54},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":17,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":322,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":4},"100645785","diagnostic-value-of-digital-infrared-thermographic-imaging-in-diagnosing-carpal-tunnel-syndrome-100645785","NCT07699289","Diagnostic Value of Digital Infrared Thermographic Imaging in Diagnosing Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* 18 years old or more\n* Were referred to the department of rehabilitation for electrodiagnostic evaluation of the disease not involved in the index hand\n* The hand of interest has cumulative score of less than 12 from CTS-6 scale\n\nExclusion Criteria:\n\n* History of hand surgery in the index hand\n* Having a condition which may alter surface temperature of the hand, for example, infection, scar in the interested area, arthritis, other peripheral neuropathy, uncontrolled diabetes mellitus, uncontrolled thyroid disease, stroke, and vascular disease\n* Having hand deformities that render collecting DITI information to calculate the parameters of interest impossible, for example, amputation of any part of the hand\n* Current medication affecting sympathetic tone\n* Severe tremors or inability to maintain standardized positioning\n* Electrodiagnosis result other than normal or carpal tunnel syndrome in the hand of interest",{"count":323,"type":23},144,"The goal of this observational study is to evaluate skin temperature patterns measured by infrared thermography in patients with carpal tunnel syndrome (CTS). The main questions it aims to answer are: Are skin temperature patterns associated with CTS as determined by 6-item CTS scale?\n\nParticipants diagnosed with CTS as part of their routine clinical care will undergo infrared thermal imaging and electrodiagnostic evaluation according to the study protocol. The relationship between thermographic findings and electrodiagnostic severity will be analyzed.",[326],"Carpal Tunnel Syndrome (CTS)",{"date":310,"type":47},{"date":329,"type":23},"2026-09-01",{"date":331,"type":23},"2027-11-30",{"name":53,"class":54},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":227,"enrollmentInfo":340,"targetDuration":4,"studyType":66,"phases":342,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":357,"leadSponsor":359,"locationsCount":108},"100644259","pilates-for-sedentary-individuals-100644259","NCT07666919","Pilates for Sedentary Individuals","Efficacy of Pilates on Core Stability and Physical Fitness Among Sedentary Individuals","Inclusion Criteria:\n\n* Aged between 18 and 59 years.\n* Had a Body Mass Index (BMI) of ≥ 23 kg\u002Fm2.\n* Engaged in sedentary activities (sitting) for more than 7 hours per day.\n* Passed the Physical Activity Readiness Questionnaire (PAR-Q) assessment.\n* Did not currently participate in any other exercise programs or physical activities during the study period.\n\nExclusion Criteria:\n\n* Had visual impairments that could not be corrected with corrective lenses or glasses.\n* Had a medical history of spinal or lower extremity surgery.\n* Had medical conditions or received medications that affected balance and gait, such as neurological diseases or benign paroxysmal positional vertigo (BPPV).\n* Pregnant during the study period.\n* Had severe pain in any part of the body (pain score ≥ 7\u002F10).\n* Inability to follow the research procedures.",{"count":341,"type":23},34,[96],"The global rise in physical inactivity represents an escalating public health crisis, with the proportion of insufficiently active adults projected to reach 35% by 2030. Office workers are at the highest risk due to prolonged occupational sitting; a lifestyle factor heavily linked to various musculoskeletal disorders. While maintaining an upright posture relies on the synergistic coordination of deep core muscles, extended sitting disrupts this muscular balance, leading to chronic postural decay. Although Pilates is proven to improve core muscle thickness, enhance physical fitness, and alleviate low back pain, existing literature shows high variability in training durations (ranging from 6 to 16 weeks) and lacks definitive conclusions regarding its long-term, residual effects post-intervention. Consequently, it remains unclear whether the benefits of Pilates can be sustained once the structured training stops. Therefore, this study aimed to investigate the efficacy of Pilates on core stability and physical fitness among sedentary individuals, providing insights into sustainable exercise interventions.",[345,346],"Sedentary Behaviors","Core Muscle Weakness",[348,349,350,351,352],"core muscle","core stability","physical inactivity","pilates","sedentary behaviors","2026-06-23",{"date":355,"type":47},"2026-06-26",{"date":283,"type":23},{"date":358,"type":23},"2027-12",{"name":53,"class":54},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":18,"minAge":367,"maxAge":63,"enrollmentInfo":368,"targetDuration":4,"studyType":66,"phases":370,"briefSummary":371,"conditions":372,"keywords":375,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":108},"100643889","artificial-intelligence-based-postural-feedback-for-scoliosis-100643889","NCT07669428","Artificial Intelligence-Based Postural Feedback for Scoliosis","The Effect of Artificial Intelligence-Based Postural Feedback on Posture Correction in Idiopathic Scoliosis Patients","Inclusion Criteria:\n\n* Diagnosis of adolescent idiopathic scoliosis (AIS) by a physician.\n* Aged between 10 and 18 years.\n* Cobb angle between 10 and 40 degrees.\n\nExclusion Criteria:\n\n* Leg length discrepancy greater than 2 cm, measured from the anterior superior iliac spine (ASIS) to the lateral malleolus.\n* Previous history of spinal surgery.\n* Musculoskeletal or neurological injuries that affect balance and gait.\n* Inability to follow the research procedures.","10 Years",{"count":369,"type":23},30,[96],"Due to advancements in technology, Posture-Analyzing and Virtual Reconstructing (PAViR) systems were developed. They used Red-Green-Blue-Depth camera sensors and artificial intelligence to evaluate human posture alignment, muscle balance, and movement without the use of radiation or physical markers. This technology served as a portable, X-ray-like device that was safe and user-friendly, providing detailed views of bone and muscle models alongside easy-to-understand 3D visualizations. However, how to utilize the data obtained from PAViR to support traditional treatment remained unclear. To fill this gap, this study aimed to investigate the effects of AI-based postural feedback on posture correction in patients with idiopathic scoliosis.",[373,374],"Postural Alignment","Idiopathic Adolescent Scoliosis",[376,377,378,379],"artificial Intelligence","posture","scoliosis","three-dimensional imaging",{"date":381,"type":47},"2026-06-25",{"date":383,"type":23},"2026-07",{"date":385,"type":23},"2027-07",{"name":53,"class":54},{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":17,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":66,"phases":396,"briefSummary":397,"conditions":398,"keywords":406,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":417,"leadSponsor":419,"locationsCount":108},"100641870","brief-bronchial-suction-for-lung-collapse-during-uniportal-vats-100641870","NCT07660588","Brief Bronchial Suction for Lung Collapse During Uniportal VATS","Effect of Brief Bronchial Suction on the Quality of Non-Ventilated Lung Collapse and Time to Adequate Surgical Exposure During Uniportal Video-Assisted Thoracoscopic Surgery: a Randomized Patient- and Surgeon-Blinded Trial","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* BMI ≤ 35 kg\u002Fm2\n* American Society of Anesthesiologists (ASA) physical status I to III\n* Scheduled for elective single-port video-assisted thoracoscopic surgery (VATS) at Siriraj Hospital\n* Requirement for one-lung ventilation using a double-lumen tube (DLT)\n* Surgery performed in the lateral decubitus position\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Previous thoracic surgery\n* Known or suspected severe pleural adhesions based on preoperative imaging or clinical history\n* Tracheobronchial anatomical abnormalities\n* Pulmonary bullae identified on chest radiography or computed tomography, or a history of recurrent pneumothorax\n* Forced vital capacity (FVC) \\\u003C 50% of predicted\n* Pregnancy",{"count":395,"type":23},100,[96],"The goal of this clinical trial is to learn whether a brief suction of the airway going to the surgical lung (bronchus) can help the lung collapse faster and more completely during uniportal video-assisted thoracoscopic surgery (UVATS). This type of surgery is performed through a small incision in the chest, and good lung collapse helps the surgeon see and work safely. The main questions it aims to answer are\n\n1. Does brief bronchial suction improve the quality of lung collapse 1 minute after chest cavity is opened?\n2. Does brief bronchial suction help reach satisfactory lung collapse faster?\n\nResearchers will compare patients who receive brief bronchial suction and those who do not. This is to see if suction improves and fastens lung collapse, reduce the need for additional steps if lung is not adequately collapsed, affect inflammation, oxygenation, postoperative pulmonary complications, operative time, and the duration of one-lung ventilation. Participants will\n\n1. Undergo UVATS under general anesthesia\n2. Have a double-lumen breathing tube placed as part of the standard anesthetic care\n3. Be randomly assigned to either receive bronchial suction for one minute or receive no bronchial suction\n4. Have the surgical team assess the quality of lung collapse at different time points\n5. Have blood samples taken for interleukin-6, a marker related to inflammation, once during and once after surgery. These samples are collected through a small tube in a vein that is placed as a standard anesthetic care while the participant is under general anesthesia. No extra puncture is required for blood collection.\n6. Have information collected from the routine anesthesia and surgical records such as oxygen levels during surgery, length of surgery and lung-related complications within 7 days after surgery",[399,400,401,402,403,404,405],"Lung Collapse","One-lung Ventilation","Thoracic Anesthesia","Thoracic Surgery, Video-assisted","Double-lumen Tube","Uniportal Video Assisted Thoracic Surgery (U-VATS)","Postoperative Pulmonary Complications",[407,408,409,410,411,412,413],"uniportal VATS","UVATS","bronchial suction","lung collapse","one-lung ventilation","double-lumen tube","thoracic anesthesia","2026-06-16",{"date":252,"type":47},{"date":283,"type":23},{"date":418,"type":23},"2028-07",{"name":53,"class":54},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":18,"minAge":428,"maxAge":429,"enrollmentInfo":430,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":108},"100637660","development-and-validation-of-the-paediatric-scale-for-quality-of-recovery-in-the-post-anaesthesia-care-unit-100637660","NCT07610915","Development and Validation of the Paediatric Scale for Quality of Recovery in the Post-Anaesthesia Care Unit","Development and Validation of the Paediatric Scale for Quality of Recovery in the Post-Anaesthesia Care Unit (PedSQoR-PACU)","PedSQoR-PACU","Inclusion criteria\n\n* Children aged 8-17 years for self-report version\n* Parents\u002Fcaregivers of children aged 2-7 years for proxy-report version\n* Elective surgery\u002Fprocedure under anaesthesia\n* Planned recovery in PACU\n* ASA I-IV\n* Able to communicate in the prespecified site language (Thai - in Siriraj Hospital site)\n* Informed consent\u002Fassent obtained as applicable Exclusion criteria\n* Unable to communicate in the prespecified site language (Thai - in Siriraj Hospital site)\n* Urgent or emergency surgery\u002Fprocedure\n* Not planned to recover in PACU, including planned direct transfer from theatre to ICU\n* Developmental delay or other condition limiting comprehension for interview participation or questionnaire completion\n* Not available for an uninterrupted interview or questionnaire completion.","2 Years","17 Years",{"count":431,"type":23},200,"This project aims to develop and test a new questionnaire to measure how well children recover in the post-anaesthesia care unit (PACU). Currently, children in PACU are mainly assessed using discharge readiness criteria, but these do not fully capture the child's recovery experience or overall wellbeing. Participants will be children aged 2-17 years having elective procedures requiring anaesthesia or sedation, and their parents\u002Fcaregivers where proxy reporting is needed for younger children. The study will be conducted in stages, including interviews to identify important aspects of recovery, expert review of draft questions, testing of question clarity and acceptability, and field testing of the questionnaire in PACU at planned time points during recovery. Clinical information routinely collected as part of care, such as pain scores, nausea vomiting, airway or oxygen events, and length of stay in PACU, will also be examined to assess how well the questionnaire performs. The expected outcome is a child-centred, practical, and reliable PACU recovery measure that can be used in clinical care, quality improvement, and future research.",[434],"Postoperative Recovery in Children",[436,437,438,439,440,441,442],"Pediatric anesthesia","Postoperative recovery","Patient-reported outcomes","Questionnaire development","Questionnaire validation","Psychometric validation","postanesthesia-care unit","2026-05-20",{"date":445,"type":47},"2026-05-28",{"date":447,"type":23},"2026-06-15",{"date":449,"type":23},"2027-07-31",{"name":53,"class":54},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":18,"minAge":428,"maxAge":429,"enrollmentInfo":459,"targetDuration":461,"studyType":25,"phases":4,"briefSummary":462,"conditions":463,"keywords":464,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":108},"100622044","thai-version-of-the-pediatric-quality-of-recovery-score-pedsqor-translation-and-psychometric-validation-study-100622044","NCT07378501","Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study","Translation and Psychometric Validation of the Thai Version of the Pediatric Quality of Recovery Score (Thai-PedsQoR)","Thai-PedsQoR","Inclusion Criteria:\n\n* Pediatric patients aged 2-17 years undergoing day surgery\u002Fintervention or surgery\u002Fintervention requiring postoperative hospital admission.\n* ASA Physical Status I-III.\n\nExclusion Criteria:\n\n* Patients or parents\u002Fguardians who are unable to communicate in Thai.\n* Urgent or emergent surgery.\n* Children with significant developmental delay or severe systemic disease that interferes with activities of daily living.\n* Parents, guardians, or patients who, in the opinion of the investigator, are unlikely to be available to complete follow-up.",{"count":460,"type":23},130,"21 Days","Postoperative recovery in children is a complex, multidimensional process that differs substantially from recovery in adults, encompassing physical comfort, emotional well-being, behavioral changes, and psychosocial functioning. While several validated Quality of Recovery (QoR) instruments are widely used in adult perioperative care, equivalent tools for pediatric populations remain limited, particularly in non-English-speaking settings. The Pediatric Quality of Recovery score (PedSQoR) was recently developed to address this gap by providing a comprehensive, patient- and proxy-reported outcome measure specifically designed for children. However, a culturally adapted and psychometrically validated Thai version of this instrument is currently unavailable.\n\nThe primary objective of this study is to translate and culturally adapt the PedSQoR into Thai in accordance with the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines for patient-reported outcome measures. The secondary objective is to evaluate the psychometric properties of the Thai-PedSQoR, including content validity, construct validity, reliability, and responsiveness, in Thai pediatric surgical patients.\n\nThis clinical applied research will be conducted at Siriraj Hospital and will include children aged 2-17 years undergoing elective surgery or procedures requiring anesthesia. The translation process will involve forward and backward translation, expert committee review, and cognitive debriefing with parents and children to ensure conceptual equivalence and cultural appropriateness. Psychometric validation will be performed in a cohort of 130 participants, stratified into proxy-report and self-report groups according to age. The Thai-PedSQoR will be administered on postoperative days 2, 6, and 21, alongside anchor measures including pain and global recovery visual analog scales.\n\nThe expected outcome of this study is a reliable and valid Thai version of the PedSQoR that can be used in clinical practice, quality improvement initiatives, and future pediatric perioperative research, supporting patient-centered and value-based pediatric surgical care in Thailand.",[434],[436,437,438,440,441],"2026-05-15",{"date":467,"type":47},"2026-05-19",{"date":469,"type":47},"2026-05-05",{"date":471,"type":23},"2027-06-30",{"name":53,"class":54},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":480,"enrollmentInfo":481,"targetDuration":4,"studyType":66,"phases":482,"briefSummary":483,"conditions":484,"keywords":488,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":503},"100636654","greater-occipital-nerve-block-for-migraine-with-medication-overuse-headache-100636654","NCT07568496","Greater Occipital Nerve Block for Migraine With Medication Overuse Headache","GONB_MOH","Inclusion Criteria:\n\n* Patients who have a diagnosis of migraine with medication overuse headache according to ICHD-3 criteria confirmed by a neurologist\n* Female patients will be screened for pregnancy planning and married female patients must undergo a urine pregnancy test\n\nExclusion Criteria:\n\n* Patients who have other types of headache disorders other than migraine\n* Patients who have a previous history of allergy to corticosteroid or lidocaine\n* Patients who had previous skull surgery\n* Pregnant women\n* Patients with a history of uncontrolled depression, or psychosis\n* Patients who get or plan to get CGRP-targeted therapies or botulinum toxin injection\n* Patients with an increased risk of bleeding or underlying bleeding disorders","80 Years",{"count":460,"type":23},[96],"Migraine is among the leading causes of disability worldwide. Inappropriate use of acute medications in the setting of primary headache, particularly migraine can result in a debilitating condition known as medication overuse headache (MOH). Treatment of MOH is challenging and the primary therapeutic approach is reducing painkillers which helps decrease the number of headache days. As a part of the detoxification process to discontinue acute medications, bridging therapy is often needed to reduce withdrawal headache. Currently, there are data supporting the use of greater occipital nerve block as a preventive treatment in chronic migraine, but no placebo-controlled trial has evaluated the efficacy of greater occipital nerve block in MOH. Therefore, this research aims to demonstrate the efficacy of greater occipital nerve block in detoxification of migraine patients with MOH. Patients will be recruited from Headache Clinic at 3 centers in Thailand from February 2026 to January 2028. After recruitment, patients will be randomized into 2 groups at a 1:1 ratio using a block of four, namely group A and B. A 5-mL syringe of 2 mL of lidocaine 2% and 2 mL of methylprednisolone 40 mg\u002FmL (80 mg) will be prepared for each patient in group while a 5-mL syringe of 4 mL normal saline will be prepared for each patient in group B. Monthly headache days, duration, severity, acute medication type and number of usage days and relative headache status according to a 5-point Likert scale will be investigated at the 2 weeks, 1st, 2nd and 3rd month, MIDAS at the end of 3rd month.",[485,486,487],"Migraine Disorders","Medication Overuse Headache","Greater Occipital Nerve Block",[489,490,491,492,493,494],"GONB","Nerve Block","Detoxification","MOH","Methylprednisolone","Lidocaine","2026-05-11",{"date":497,"type":47},"2026-05-13",{"date":499,"type":23},"2026-05-01",{"date":501,"type":23},"2028-11-01",{"name":53,"class":54},3,{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":66,"phases":512,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":525,"leadSponsor":527,"locationsCount":108},"100638344","bis-in-critically-ill-patients-in-icu-100638344","NCT07583732","BIS in Critically Ill Patients in ICU","The Comparison of Bispectral Index Parameter Between Critically Ill Patients With and Without Decreased Mental Status and Its Association With Clinical Outcomes","Inclusion Criteria:\n\n1. Age≥18years\n2. RASS score ≤ -3 as case\n3. RASS score 0 to -1 as control\n4. Expected ICU length of stays ≥ 24hours\n\nExclusion Criteria:\n\n1. Contraindication for BIS monitoring (wound or infection at forehead)\n2. No space for attach BIS monitoring at forehead\n3. Patient with sedative drugs (Propofol, Midazolam, Dexmedetomidine)\n4. Patient with acute stroke\n5. Patient was already on EEG monitoring\n6. Denied by patients or patient's surrogates",{"count":149,"type":23},[96],"The Bispectral Index (BIS) is a monitor that converts brain electrical activity from EEG into a simple number from 0 to 100. A higher number means the patient is more awake, while a lower number means deeper sedation or reduced brain activity.\n\nIn general, 100 means fully awake, 80 suggests light to moderate sedation, 60 is commonly used as a target for general anesthesia with a low chance of awareness, 40 indicates deep anesthesia, 20 suggests marked brain suppression with burst suppression on EEG, and 0 indicates no detectable cortical electrical activity.\n\nAlthough BIS was originally developed for use in the operating room, it has also been applied in the ICU to help guide sedation, avoid over- or under-sedation, and assess consciousness in patients who cannot be evaluated reliably using standard clinical scores. BIS has also been studied as a possible tool for predicting outcomes in comatose ICU patients, such as those after cardiac arrest, stroke, encephalitis, or traumatic brain injury. However, evidence is still limited for its use in predicting outcomes among ICU patients with any form of decreased consciousness. Therefore, this study was conducted to explore that role.",[515],"Critically Ill Patients",[517,518,519,520,521],"BIS","processed EEG","ICU patient","Sedation","Neuromonitoring","2026-05-06",{"date":497,"type":47},{"date":465,"type":23},{"date":526,"type":23},"2027-03-31",{"name":53,"class":54},{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":480,"enrollmentInfo":535,"targetDuration":4,"studyType":66,"phases":537,"briefSummary":538,"conditions":539,"keywords":545,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":553,"locationsCount":108},"100633097","phase-3-rifaximin-treatment-in-bloating-predominant-functional-bowel-disorders-100633097","NCT07522255","Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders","The Effect of Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders: A Randomized Double-blind Placebo-Controlled Trial With Gut Microbiota and Intestinal Gas Analysis","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Rome IV diagnosis of irritable bowel syndrome, functional constipation, or functional abdominal bloating\u002Fdistension.\n* Bothersome bloating with baseline severity of at least 3 on a 7-point Likert scale after adequate constipation treatment, defined as stool frequency from at least 3 times\u002Fweek to 3 times\u002Fday and Bristol Stool Form Scale type 3-5.\n* Colonoscopy, CT colonography, or barium enema performed if clinically indicated as part of standard evaluation for bowel symptoms.\n\nExclusion Criteria:\n\n* History of major gastrointestinal surgery, except appendectomy or laparoscopic cholecystectomy.\n* Inflammatory bowel disease or other inflammatory gastrointestinal conditions.\n* Current use of, or inability to discontinue, medications that may affect intestinal microbiota or gas measurements, including antibiotics, proton pump inhibitors, probiotics, lactulose, NSAIDs, or metformin.\n* Current use of, or inability to discontinue, medications that may affect bloating symptoms, including simethicone, simethicone-containing antispasmodics, or antidiarrheal medications.\n* Underlying conditions known to affect intestinal microbiota composition, including cirrhosis, uncontrolled diabetes mellitus, end-stage renal disease, obesity, malignancy, or psychiatric disorders.\n* Opioid-induced constipation.\n* Known allergy to rifaximin.",{"count":536,"type":23},78,[268],"This randomized, double-blind, placebo-controlled trial will evaluate whether a 14-day course of rifaximin improves bloating in adult patients with Rome IV functional bowel disorders in whom bloating is the predominant symptom. Eligible participants with irritable bowel syndrome, functional constipation, or functional abdominal bloating\u002Fdistension and bothersome bloating despite adequate bowel movement management will be assigned in a 1:1 ratio to rifaximin 550 mg three times daily or matching placebo for 2 weeks. The primary endpoint is the proportion of participants with bloating response, defined as at least a 1-point reduction from baseline in a 7-point Likert bloating score at the end of treatment.",[540,541,542,543,544],"Bloating","Rifaximin","Functional Bowel Disorder","Irritable Bowel Syndrome","Constipation",[541,540,546],"Functional bowel disorder","2026-04-03",{"date":549,"type":47},"2026-04-13",{"date":551,"type":23},"2026-04",{"date":358,"type":23},{"name":53,"class":54},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":66,"phases":563,"briefSummary":564,"conditions":565,"keywords":567,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":108},"100606416","phase-2-holy-basil-in-the-treatment-of-dyspepsia-100606416","NCT07175272","Holy Basil in The Treatment of Dyspepsia","Evaluation of The Effect of Holy Basil in The Treatment of Patients With Dyspepsia","Inclusion Criteria:\n\n* Participants aged 18 years and older.\n* Presence of dyspeptic symptoms, assessed by the Leeds Dyspepsia Questionnaire with a score of at least 5 or higher.\n\nExclusion Criteria:\n\n* Presence of Helicobacter pylori infection.\n* Diagnosis of peptic ulcer or erosive esophagitis Los Angeles Classification grade B or greater.\n* Use of acid-suppressant therapy including proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) that cannot be discontinued at least 2 weeks prior enrolment and during the study period.\n* Use of mucosal protective agents, such as rebamipide, sucralfate, or irsogladine that cannot be discontinued at least 4 weeks prior enrolment and during the study period.\n* History of gastric cancer or duodenal cancer.\n* Previous upper gastrointestinal surgery.\n* Current pregnancy or lactation.\n* Known allergic to the medicine.",{"count":562,"type":23},27,[152,268],"The goal of this clinical trial is to evaluate whether holy basil extract can reduce gastric inflammation and improve symptoms in adult patients with dyspepsia.\n\nThe main questions it aims to answer are:\n\n* Does holy basil extract reduce gastric mucosal inflammation as measured by histopathology?\n* Does holy basil extract improve dyspeptic symptoms, endoscopic findings, gastric pH, duodenal eosinophil counts, and systemic inflammation (serum IL-6)?\n\nParticipants will:\n\n* Take 300 mg of holy basil extract orally once daily for 28 days\n* Complete symptom questionnaires and diaries during treatment\n* Undergo upper endoscopy with biopsy and intragastric pH monitoring before and after treatment\n* Provide blood samples for inflammatory marker measurement\n* Be monitored for safety and adverse events",[566],"Dyspepsia and Other Specified Disorders of Function of Stomach",[568,569,570],"Dyspepsia","Gastritis","Holy basil","2026-03-23",{"date":573,"type":47},"2026-03-24",{"date":575,"type":47},"2026-02-13",{"date":577,"type":23},"2026-12",{"name":53,"class":54},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":587,"enrollmentInfo":588,"targetDuration":4,"studyType":66,"phases":590,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":4},"100615011","a-single-blind-randomized-controlled-study-comparing-the-efficacy-of-high-intensity-laser-therapy-and-focused-extracorporeal-shock-wave-therapy-in-patients-with-plantar-fasciitis-100615011","NCT07287046","A Single-Blind Randomized Controlled Study Comparing the Efficacy of High-Intensity Laser Therapy and Focused Extracorporeal Shock Wave Therapy in Patients With Plantar Fasciitis","A Comparison of Efficacy Between High-intensity Laser Therapy and Focused Extracorporeal Shock Wave Therapy in Patient With Plantar Fasciitis; Single Blinded Randomize Controlled Study","HILT","Inclusion Criteria:\n\n* Patients aged 18-70 years\n* Pain was worse in the initial step after and an extended period of rest\n* Pain was decreased initially after the first steps but exacerbated with increased activity\n* VAS ≥ 4\n* Pain was localized and sharp but not radiating,\n* Pain was reproduced with palpation of the plantar fascia\n\nExclusion Criteria:\n\n* Have Wound\u002FInfection\u002Ftumor in treatment area\n* History of foot trauma in 3 months\n* History of intervention at plantar fascia in 6 months such as Ultrasound therapy, steroid injection, surgery or botulinum toxin injection\n* Pain medication within one week before participation\n* Patient wasn't desired to participate in the study","70 Years",{"count":589,"type":23},28,[96],"This randomized controlled trial aims to evaluate the efficacy of High-Intensity Laser Therapy (HILT) and Focused Extracorporeal Shock Wave Therapy (fESWT) in reducing pain in patients with plantar fasciitis. The study also examines the effects of HILT and fESWT on health-related outcomes, including VAS-FA, FFI, plantar fascia thickness, and adverse events.\n\nResearchers will compare HILT with fESWT as treatment options for patients with plantar fasciitis.\n\nParticipants will receive either HILT or fESWT along with an exercise program. They will attend follow-up visits to assess outcomes at 1, 2, 3, 6, and 12 weeks after the first treatment.",[593],"Plantar Fasciitis","2026-03-20",{"date":134,"type":47},{"date":597,"type":23},"2026-02-28",{"date":599,"type":23},"2027-02-20",{"name":53,"class":54},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":18,"minAge":608,"maxAge":609,"enrollmentInfo":610,"targetDuration":4,"studyType":66,"phases":612,"briefSummary":613,"conditions":614,"keywords":617,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":108},"100630269","effects-of-invisalign-palatal-expander-vs-rapid-palatal-expander-with-facemask-in-growing-class-iii-patients-100630269","NCT07485478","Effects of Invisalign Palatal Expander vs Rapid Palatal Expander With Facemask in Growing Class III Patients","Effects of the Invisalign® Palatal Expander (IPE) vs. Rapid Palatal Expander With Facemask in Growing Skeletal Class III Patients: A CBCT Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients aged between 8 and 12 years\n* Patients in the mixed dentition or early permanent stage have at least three stable teeth per quadrant, good oral hygiene, and healthy periodontal tissues\n* Patients with maxilla-mandibular discrepancies; skeletal class III is indicated by an ANB angle \\\u003C 0 degrees or a Wits appraisal value that is negative, and Maxillary constriction is characterized by posterior crossbite teeth or having a maxillary width below the norm value.\n\nExclusion Criteria:\n\n* Patients with craniofacial anomalies such as cleft lip and palate\n* Patient with a prior history of maxillary expansion.\n* Patients who have systemic conditions that contraindicate orthodontic treatment.","8 Years","12 Years",{"count":611,"type":23},24,[96],"The goal of this clinical trial is to compare two types of palatal expanders used with a facemask in children who have skeletal Class III and a narrow upper jaw. The study will compare the Invisalign Palatal Expander (IPE) and the Rapid Palatal Expander (RPE). Researchers want to learn how these devices affect jaw bones and tooth position. They also want to learn about children's and parents' experiences during treatment.\n\nThe main questions this study aims to answer are:\n\nDo IPE and RPE widen the upper jaw differently?\n\nDo they cause different changes in tooth position?\n\nHow do children and parents describe their treatment experience?\n\nParticipants will be children aged 8 to 12 years who have skeletal Class III and a narrow upper jaw. Children with craniofacial conditions, previous upper jaw expansion, or medical conditions that prevent orthodontic treatment will not take part. Parents and children must give consent before joining the study.\n\nParticipants will:\n\nBe assigned to receive either IPE or RPE\n\nExpand the upper jaw to 7 mm (0.25 mm per day)\n\nAfter expansion, wear a facemask for at least 12 hours per day for 6 to 8 months\n\nHave cone-beam computed tomography (CBCT) scans taken before expansion, after expansion, and after facemask treatment\n\nTake part in an interview with a parent after expansion\n\nResearchers will use CBCT images to measure changes in jaw bones and tooth position. The main outcomes are changes in jaw bones and tooth position. Secondary outcomes include children's and parents' experiences during treatment.",[615,616],"Skeletal Class III Malocclusion","Transverse Maxillary Deficiency",[618,619,620,621,622],"Invisalign Palatal Expander","Rapid Palatal Expansion","Facemask","CBCT","Retrognathic maxilla","2026-03-16",{"date":594,"type":47},{"date":626,"type":23},"2026-03",{"date":628,"type":23},"2027-10",{"name":53,"class":54},{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":636,"eligibilityCriteria":637,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":638,"targetDuration":4,"studyType":66,"phases":640,"briefSummary":641,"conditions":642,"keywords":644,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":108},"100627432","tailored-exercise-to-reduce-aromatase-inhibitor-associated-musculoskeletal-symptoms-100627432","NCT07448558","Tailored Exercise to Reduce Aromatase Inhibitor Associated Musculoskeletal Symptoms","Effectiveness of Tailored Home-based Exercise on Aromatase Inhibitor-associated Musculoskeletal Symptoms in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitor: A Randomized, Controlled Trial","TAILOR-Ex","Inclusion Criteria:\n\n* breast cancer patients with starting adjuvant aromatase inhibitor within 4 weeks\n* able to read and write\n\nExclusion Criteria:\n\n* chronic arthritis\n* history of heart failure or acute coronary syndrome within 6 months\n* individuals who exercises regularly more than 150 minutes\u002Fweek",{"count":639,"type":23},206,[96],"A randomized controlled study evaluating effect of tailored exercise compared to routine practice as a preventive measure of aromatase inhibitor associated musculoskeletal related symptoms in early breast cancer patients",[643],"Patients With Early Breast Cancer Who Initiating Adjuvant Aromatase Inhibitor",[645,646,647,648],"exercise","aromatase inhibitor","musculoskeletal associated symptoms","ิbreast cancer","2026-02-26",{"date":651,"type":47},"2026-03-04",{"date":653,"type":47},"2026-02-18",{"date":655,"type":23},"2029-08-18",{"name":53,"class":54},{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":665,"targetDuration":667,"studyType":25,"phases":4,"briefSummary":668,"conditions":669,"keywords":671,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":683,"locationsCount":108},"100626643","septic-shock-hemodynamic-respond-to-volume-resuscitation-versus-vasopressor-administration-100626643","NCT07438301","Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration","Echocardiographic Assessment the Different of Septic Shock Resuscitation: Comparison of Volume Expansion Versus Vasopressor Administration","ECHO-VEVA","Inclusion Criteria:\n\n* Adult patients aged ≥18 years\n* Diagnosis with Septic Shock (Sepsis-3 Definition of Septic Shock)\n* Hypotension, SBP \\\u003C 90 mmHg, or mean arterial BP \\\u003C 65 mmHg\n\nExclusion Criteria:\n\n* Patients who receive two or more vasopressors\n* Patients who receive inotropic medications\n* Patients who receive simultaneously fluid with vasopressor resuscitation\n* Patients with insufficiently quality ultrasound images for determining echocardiography\n* Patients or their legally authorized representatives (LAR), who decline participation in the study or are unable to provide informed consent before enrollment",{"count":666,"type":23},180,"28 Days","The goal of this observational study is to learn about the change of hemodynamic response from intravenous fluid versus medical (vasopressor) resuscitation by echocardiogram in septic shock patient.\n\nThe main question it aims to answer is:\n\nHow hemodynamic response change from intravenous fluid versus medical (vasopressor) resuscitation by echocardiogram in septic shock patient?\n\nParticipants already receiving the appropriate resuscitation at that time by their medical staff as part of their regular medical care for septic shock. The echocardiogram will assess before and after resuscitation.",[670],"Septic Shock",[672,673,674,675],"sepsis","septic shock","hemodynamic","echocardiogram","2026-02-22",{"date":678,"type":47},"2026-02-27",{"date":680,"type":23},"2026-03-15",{"date":682,"type":23},"2028-01-31",{"name":53,"class":54},{"id":685,"slug":686,"hasResults":12,"nctId":687,"briefTitle":688,"officialTitle":688,"acronym":4,"eligibilityCriteria":689,"healthyVolunteers":12,"sex":18,"minAge":63,"maxAge":480,"enrollmentInfo":690,"targetDuration":4,"studyType":66,"phases":692,"briefSummary":693,"conditions":694,"keywords":699,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":704,"lastUpdatePostDateStruct":705,"startDateStruct":707,"completionDateStruct":709,"leadSponsor":711,"locationsCount":108},"100626310","changes-in-hemodynamic-response-following-transcranial-electrical-stimulation-in-sroke-individuals-100626310","NCT07433972","Changes in Hemodynamic Response Following Transcranial Electrical Stimulation in Sroke Individuals","Inclusion Criteria:\n\n1. Unilateral stroke individuals aged 18-80 years.\n2. A first-ever stroke.\n3. Stroke onset from at least 2 weeks-5 years.\n4. Able to walk independently with or without gait aids (modified Rankin scale (mRS) 1-3)\n5. Montreal cognitive Assessment-Thai version (MoCA-T) greater than or equal to 20 scores.\n6. Ability to read, communicate, follow and understand instructions.\n\nExclusion Criteria:\n\n1. Presence of any psychological or neurological antecedent, unstable medical conditions or condition that may increase risk of stimulation such as epilepsy, seizure, and history of brain injury\n2. Having unstable cardiovascular disease or respiratory disease, and uncontrolled chronic disease such as diabetes mellitus (DM), hypertension (HT) and chronic kidney disease (CKD)\n3. Receiving other non-invasive brain stimulation or additional intervention such as TMS, PMS or acupuncture\n4. Presence of metal implantation, intracranial shunt, cochlear implantation, or cardiac pacemakers.\n5. Presence of an opened wound, infectious wound around scalp or craniectomy with unreplaced bone flap\n6. Moderate pain (numeric pain rating score \\> 4\u002F10) in any joint of the upper or lower limb, whether paretic or non-paretic\n7. Presence of color blindness\n8. Presence of any substance use including cannabis and kratom",{"count":691,"type":23},60,[96],"The present study will use transcranial electrical stimulation (tES) which are transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) combined with conventional physical therapy and cognitive-motor dualt ask gait training in sub-acute (at least 2 weeks after stroke onset) to chronic stroke (within 5 years post-stroke) to investigate changes in brain hemodynamics (oxy-hemoglobin and deoxy-hemoglobin concentration) as measured by functional near infrared spectroscopy (fNIRS). The findings may provides insights changes in combining tES with rehabilitation on improvements in brain hemodynamics in sub-acute to chronic stroke.",[695,696,697,698],"Hemorrhagic Stroke","Ischemic Stroke","Subacute Stroke","Chronic Stroke Survivors",[700,701,702,703],"Stroke","functional near-infrared spectroscopy","rehbailitation","transcranial electrical stimulation","2026-02-19",{"date":706,"type":47},"2026-02-25",{"date":708,"type":23},"2026-03-01",{"date":710,"type":23},"2026-12-30",{"name":53,"class":54},""]